Related Experiment Video

Updated: Jun 19, 2025

Microbial Communities in Nature and Laboratory - Interview
29:13

Microbial Communities in Nature and Laboratory - Interview

Published on: May 28, 2007

6.2K

Escape Velocity-the Launch of Microbiome Therapies

Brendan J Kelly1, Jennie H Kwon2, Michael H Woodworth3

  • 1Department of Medicine, Division of Infectious Diseases, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

The Journal of Infectious Diseases
|July 25, 2024
PubMed

Insights

The first FDA-approved microbiome therapies expand Clostridioides difficile treatment options. Fecal microbiota transplantation (FMT) limitations in safety and scalability are being addressed by new microbiome therapeutics.

Area of Science:

  • Microbiology
  • Gastroenterology
  • Therapeutics Development

Background:

  • Clostridioides difficile infection (CDI) poses a significant clinical challenge.
  • Fecal microbiota transplantation (FMT) has shown efficacy but faces safety and scalability issues.
  • Recent Food and Drug Administration (FDA) approvals mark a new era for microbiome-based therapies.

Purpose of the Study:

  • To review advances in microbiome therapeutic development.
  • To discuss how these advances address limitations of FMT.
  • To explore the future role of FMT in translational research.

Main Methods:

  • Literature review of microbiome therapeutic development.
  • Analysis of FDA-approved microbiome therapies.
  • Discussion of FMT's role in understanding microbiota dynamics.

Main Results:

  • Microbiome therapeutics are overcoming FMT's safety and scalability challenges.
  • FDA approval signifies a shift towards standardized microbiome treatments.
  • FMT remains a valuable model for studying human microbiota.

Conclusions:

  • Microbiome therapeutics offer a promising alternative to FMT for CDI.
  • Continued development of microbiome therapies is expected for various indications.
  • Fecal microbiota transplantation will persist as a crucial research tool.
Keywords:
C. difficileFDAfecal microbiota transplantationmicrobiomemicrobiota therapeutics

More Related Videos

Isolation of Soil Microorganisms Using iChip Technology05:33

Isolation of Soil Microorganisms Using iChip Technology

Published on: January 10, 2025

882
Co-culture of Living Microbiome with Microengineered Human Intestinal Villi in a Gut-on-a-Chip Microfluidic Device10:51

Co-culture of Living Microbiome with Microengineered Human Intestinal Villi in a Gut-on-a-Chip Microfluidic Device

Published on: August 30, 2016

22.4K

Related Concept Videos

Factors Influencing Bioavailability: First-Pass Elimination01:23

Factors Influencing Bioavailability: First-Pass Elimination

When a drug is taken orally, it undergoes a journey starting from the gastrointestinal (GI) tract, passing through the portal vein, reaching the liver, and finally entering the systemic circulation. This process involves the absorption of the drug across the GI tract. The liver is the primary site for metabolizing the drug, with some metabolism also occurring in the gut wall. This journey significantly reduces the quantity of the drug that reaches the systemic circulation, a phenomenon known as...
6.3K
Surface Membrane Barriers01:18

Surface Membrane Barriers

The skin and mucous membranes serve as the primary line of defense against pathogens by providing both physical and chemical protection. These barriers are essential in preventing the entry and establishment of microbes, thereby maintaining the integrity of the host.
The outer layer of the skin, the epidermis, is a robust barrier comprising layers of closely packed keratinized cells. This dense arrangement prevents microbes from penetrating the body. The periodic shedding of epidermal cells...
1.1K